Loading...
Images of Barbara Kornek
(0 from 0 )News
Natalizumab may be second-line option for pediatric MS patients
www.news-medical.net
Natalizumab may be an effective and well tolerated second-line treatment for pediatric patients with highly active relapsing-remitting multiple sclerosis, say...
Natalizumab shows promise for teens with multiple sclerosis
medicalxpress.com
Barbara Kornek, M.D., from the Medical University of Vienna, and colleagues retrospectively reviewed data on 20 pediatric patients with MS who started treatment …
Immunology | Natalizumab may be second-line option for pediatric MS...
www.medwirenews.com
medwireNews: Natalizumab may be an effective and well tolerated second-line treatment for pediatric patients with highly active relapsing-remitting
Natalizumab Therapy Examined for Pediatric Multiple Sclerosis - For...
media.jamanetwork.com
A study by Barbara Kornek, M.D., of the Medical University of Vienna, Austria, suggests that natalizumab, a humanized monoclonal antibody, ...
sorted by relevance / date